Experimental evidence suggests that LUNX may be considered as a diagnostic biomarker for lung cancer and be able to determine micro-metastases in lymph nodes of NSCLC patients and peripheral blood [15, 16]. Here, BPIFA1 is linked to lung carcinoma.